Drug intelligence / Profile preview

EuBalance

Development stage
Unknown
Lead developer
Libytec Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

EuBalance is a dietary supplement developed by Libytec Pharmaceutical, specifically formulated to support women with Polycystic Ovary Syndrome (PCOS) and metabolic imbalances such as insulin resistance. The product contains a combination of myo-inositol and d-chiro-inositol in a physiological 40:1 ratio, along with folic acid and manganese. The mechanism of action centers on the role of inositol isomers as second messengers in insulin signaling; myo-inositol and d-chiro-inositol help restore insulin sensitivity and regulate glucose metabolism, which are frequently impaired in PCOS patients. Additionally, these components support ovarian function and hormonal balance, potentially improving reproductive outcomes and managing symptoms like irregular cycles and hyperandrogenism. Folic acid is included to support DNA synthesis and homocysteine metabolism, while manganese acts as a cofactor for various metabolic enzymes.

Brand names
EuBalance
02

Targets

INSR (Insulin receptor)FOLR1 (FRα)

Beyond the preview

Go deeper on EuBalance.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EuBalance.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call